Biogen Shares Slide After Diranersen Phase 2 Shows Strong Tau Clearance but Perplexing Dose Response
Biogen Inc. shares fell nearly 9% after Phase 2 CELIA results for its Alzheimer’s candidate, diranersen, delivered striking reductions in tau biomarkers but failed to show a dose-dependent clinical benefit on the CDR-SB. The trial produced a paradoxical outcome in which the lowest dose produced the largest clinical signal, while higher doses produc…